An anti-mucin immunotoxin BrE-3-ricin A-chain is potently and selectively toxic to human small-cell lung cancer

Int J Cancer. 1992 Oct 21;52(4):624-30. doi: 10.1002/ijc.2910520422.

Abstract

Monoclonal antibodies (MAbs) known to recognize epithelial mucin or defined carbohydrate structures present on mucin molecules were screened for their ability to form cytotoxic agents with ricin A-chain active against human small-cell lung cancer (SCLC) in an indirect assay of immunotoxin cytotoxicity. Anti-X hapten and anti-Y hapten antibodies binding to a high proportion of SCLC cells mediated only weak to moderate effects on 3H-leucine incorporation in combination with the screening agent, sheep anti-mouse IgG F'ab-ricin A-chain. In contrast, the mouse MAb BrE-3, recognizing the polypeptide core of the MUCI mucin gene product, exerted potent and selective cytotoxic effects in the assay. An immunotoxin made by the direct attachment of ricin A-chain to BrE-3 was selectively toxic to SCLC cell lines in tissue culture. The cytotoxic activity of BrE-3-ricin A-chain was enhanced 100-fold in the presence of monensin but not by lysosomotropic amines or calcium antagonists. Our findings suggest that anti-mucin immunotoxins may have a therapeutic role to play in the treatment of SCLC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Carcinoma, Small Cell / pathology*
  • Carcinoma, Small Cell / therapy
  • Fluorescent Antibody Technique
  • Humans
  • Immunotoxins / pharmacology*
  • Lung Neoplasms / pathology*
  • Lung Neoplasms / therapy
  • Mice
  • Mucins / immunology*
  • Ricin / pharmacology*
  • Tumor Cells, Cultured / drug effects

Substances

  • Antibodies, Monoclonal
  • Immunotoxins
  • Mucins
  • Ricin